Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | USP7 | Q93009 | 5/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784588 | 0.81 | MAP4K4 (0.69) | MAP4K4HSP90AB1BRD4BRD2PTGS2 | |
| SCHEMBL12362813 | 0.81 | BRD4 (0.66) | BRD4BRD2MLYCD | |
| Hydrochloric Acid SCHEMBL23174957 | 0.79 | BRD4 (0.63) | BRD4BRD2MLYCD | |
| SCHEMBL7944361 | 0.77 | MAP4K4 (0.55) | MAP4K4HSP90AB1JAK2BRD4BRD2 | |
| SCHEMBL15248893 | 0.74 | BRD4 (0.55) | HSP90AB1SENP1BRD4BRD2PTGS2 | |
| SCHEMBL6251637 | 0.74 | PTGS2 (0.80) | HSP90AB1BRD4BRD2PTGS2PTGS1 | |
| SCHEMBL5427092 | 0.74 | PTGS2 (0.80) | HSP90AB1BRD4BRD2PTGS2PTGS1 | |
| SCHEMBL15836992 | 0.73 | MAP4K4 (0.47) | MAP4K4USP7JAK2BRD4 | |
| SCHEMBL12800390 | 0.72 | BRD4 (0.43) | USP7HSP90AB1JAK2BRD4BRD2 | |
| SCHEMBL15815842 | 0.71 | MAP4K4 (0.49) | MAP4K4USP7JAK2BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAP4K4 3120/4885USP7 2888/4885HSP90AB1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.